Medindia

X

InterMune to Present at Deutsche Bank Biotech Confab

Saturday, December 12, 2009 Press Release J E 4
Advertisement


BRISBANE, Calif., Dec. 11 InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and has submitted a New Drug Application (NDA) to the FDA. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (RG7227) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Liberator Medical Strengthens its Board of Directo...
S
Insurance Department Takes Actions Against HealthA...